

Contents

Overview

Colony Stimulating Factors: Past and Future <i>D. Metcalf</i>	3
Regulation of Hematopoietic Progenitor Cell Growth by Stimulating and Suppressing Cytokines <i>H.E. Broxmeyer</i>	9
Cytokine Interactions in Normal and Malignant Hematopoiesis <i>N.A. Cicco, W. Oster, A. Lindemann, R. Mertelsmann, and F. Herrmann</i>	15

Preclinical and In Vitro Data

Colony Stimulating Factors in Normal Hematopoiesis	29
Screening the Sensitivity of Hematopoietic Progenitor Cells to Different Growth Factors. Potential Importance in Therapy Trials with Colony Stimulating Factors <i>K. Vehmeyer, T. Liersch, G. Krieger, J.H. Beyer, and G.A. Nagel</i>	29
Effect of Human Recombinant Interleukin-3 in Long-term Bone Marrow Culture <i>R. Haas, D. Schwarz, S. Hohaus, E. Ogniben, G. Wulf, and W. Hunstein</i>	37
Secretion of Colony-Stimulating Factor for Macrophages (M-CSF) and Granulocyte/Macrophages (GM-CSF) is Developmentally Regulated in Human Macrophages <i>C. Scheibenbogen, G. Zenke, B. Faggs, K. Motoyoshi, L. Kanz, H. Sawert, W. Brugger, and R. Andreesen</i>	45
Expression of the M-CSF/CSF-1 Gene in Normal Human Alveolar Macrophages <i>H. Kreipe, H.J. Radzun, K. Heidorn, J. Barth, and M.R. Parwaresch</i>	53

Surface Expression of Interleukin-2 Receptors and CD4 Molecules by Human Eosinophils is Induced by GM-CSF and IL-3 <i>D. Riedel, M. Brach, R. Mertelsmann, and F. Herrmann</i>	59
Expression of Interleukin Receptors on Human Eosinophils, Basophils, and Mast Cells <i>P. Valent, J. Besemer, H. Stockinger, E. Liehl, and P. Bettelheim</i>	67
Chemiluminescence of Polymorphonuclear Leukocytes in Response to Interferons <i>M. Suttrop, U. Barzantny, and M. Rister</i>	73
Glycolysis and Amino Acid Incorporation in IL-3-Dependent Cell Lines <i>G. Reisbach, J. Ellwart, and P. Dörmer</i>	81
Fibroblast Colony Stimulating Activity of GM-CSF and IL-3 in Human Bone Marrow Cell Cultures <i>P. Valent, K. Geissler, P. Kahls, and P. Bettelheim</i>	85
Chromatin and DNA Methylation Changes of the Human Myeloperoxidase Gene During Myeloid Differentiation <i>M. Lübbert, C.W. Miller, R. Mertelsmann, F. Herrmann, and H.P. Koefler</i>	91
Retroviral-Mediated Transfer of Genes Encoding for Growth Factors into Human Hematopoietic Stem Cells <i>A.A. Fauser, P. Laneuville, R. Tellier, G. Egert, and G.W. Löhr</i>	103
Colony Stimulating Factors in Malignant Hematopoiesis	107
Recruitment Therapy in Acute Myeloblastic Leukemia: A Different Approach to Improved Leukemia Treatment <i>A. Tafuri and M. Andreeff</i>	107
Effects of Hematopoietic Growth Factors on Myelodysplastic Syndrome Progenitors <i>X. Thomas, L. Campos, L. Vila, Z.H. Shi, D. Guyotat, and D. Fiere</i>	115
Combined Cytogenetic and Proliferation Studies of GM-CSF-Stimulated Bone Marrow Cells in Myelodysplasia and Acute Leukemia <i>D. Haase and C. Fonatsch</i>	123
Recombinant Haemopoietic Factors (IL-3, IL-4, GM-CSF) Fail to Induce the Expression of Leucocyte Adhesion Receptors on Leukaemia Myeloid Colonies <i>E.S. Gussetis, J. Cinatl, B. Kornhuber, and V. Gerein</i>	129

In Vitro Evaluation of Antiproliferative Activity of CCRF-CEM Supernatant on Lymphoid and Nonlymphoid Leukemic Cells <i>R. Perricone, M. Tolomeo, R. Petruzzella, C. Tomaselli, A. Costa, E. Caravello, V. Abbadessa, and A. Cajozzo</i>	135
TNF- α , IL-6, and Phorbol Ester but Not G-, M-, GM-CSF, IL-3, and IL-4 Induce Monocytic Differentiation and Modulate Expression of <i>C-FOS</i> , <i>C-FMS</i> , and <i>C-MYC</i> in the Human Monoblast Line THP-1 <i>M. Brach, D. Riedel, R. Mertelsmann, and F. Herrmann</i>	141
In Vitro and In Vivo Inhibitory Effects of Interferon α 2b on CML Granuloerythroid Precursors <i>A. Sandrelli, P. De Fabritiis, G. Meloni, A. Cafolla, F. Simone, G. Di Matteo, M. Nanni, and F. Mandelli</i>	149
Several Cytokines Do Not Influence Activity of P210 ^{BCR-ABL} Kinase in K562 Cells <i>A. Kabisch, T. Tamura, and H. Pralle</i>	157
Colony Stimulating Factors in Nonhematopoietic Cells	163
Target Cell Specificity of Hematopoietic Growth Factors <i>A.-R. Hanauske</i>	163
Growth Factor-Dependent Stimulation of Primary Human Tumor Cells <i>H. Depenbrock, J. Trijssenaar, D. Neukam, H.-J. Meyer, M. Freund, H. Poliwoda, and A.-R. Hanauske</i>	173
Stimulation of Colony Formation of Various Human Carcinoma Cell Lines by rhGM-CSF and rhIL-3 <i>D. Nachbaur, H. Denz, H. Zwierzina, F. Schmalzl, and H. Huber</i>	181
Effects of Recombinant Cytokines on Clonogenic Cells from Primary Human Tumors <i>M. Joraschkewitz, J. Trijssenaar, M. Freund, D. Neukam, D. Krumwieg, H.-J. Meyer, H. Poliwoda, and A.-R. Hanauske</i>	189
Tumor Necrosis Factor and Interferon	197
Mechanisms of TNF Action: Analysis of Receptor Structure and of Regulatory Circuits Controlling Receptor Expression and TNF-Production <i>K. Pfizenmaier, B. Thoma, S. Schütze, M. Krönke, and P. Scheurich</i> ...	197

Synergism of Lymphotoxin and Interferon- γ in the Growth Inhibition of Breast Cancer Cell Line MCF-7 <i>C. Buck, A. Wawer, W. Mach, W. Digel, A.M. Otto, H. Schönenberger, and F. Porzsolt</i>	205
In Vitro Effect of Human Interferon-Gamma on Sister Chromatid Exchange Frequency and Proliferation of Cultured Human Amniotic Fluid Cells <i>R. Mertens, R. Flock, H. Habedank, and G. Heimann</i>	211
Tumor Necrosis Factor/Cachectin Production by B-Cell Chronic Lymphocytic Leukemia and Hairy Cell Leukemia Cells <i>R. Foa, M. Massaia, A. Gillio Tos, S. Cardona, A. Guarini, A. Bianchi, C. Attisano, P. Francia di Celle, and M.T. Fierro</i>	217
Interleukin-2	223
Activation of Cytolytic Effector Cells <i>R.E. Schmidt, W. Kolanus, and J. Schubert</i>	223
Regulatory Effect of Recombinant Cytokines on NK Cell Differentiation from Early Marrow Precursors <i>C.A. Keever, M.V. Gazzola, K. Pekle, J.H. Bourhis, and A. Gillio</i>	227
Human NK Clones Regulate B-cell Development by Release of IFN- γ and TNF- α <i>W. Kolanus, J. Becker, and R.E. Schmidt</i>	237
Expression of High Affinity IL-2 Receptors on a Hodgkin Cell Line <i>H. Tesch, T. Herrmann, H. Abts, T. Diamantstein, S. Klein, M. Schaadt, and V. Diehl</i>	245
Autologous Antileukemia Cytotoxicity Induced by PBL and BM Culture with rIL-2; Use in Autologous BMT for Inducing GVL? <i>F. Bernaudin, F. Beaujean, M. Kuentz, S. Lemerle, F. Lelong, P. Reinert, J.P. Vernant, J.F. Bernaudin</i>	253
Interleukin-2-Induced Lymphokine-Activated Killer (LAK) Cells Against Human Leukemia: Improvement of Cytotoxicity by Combinations of Lymphokines or Cytokines <i>J.V. Teichmann, W.-D. Ludwig, E. Adler, and E. Thiel</i>	263
Interleukin-2 (IL-2) in Acute Leukemia: In Vitro Studies and Possible Clinical Applications <i>R. Foa, M.T. Fierro, A. Gillio Tos, S. Cardona, A. Guarini, P. Caretto, S. Tosti, G. Meloni, F. Mandelli, G. Forni, and F. Gavosto</i> ..	271

Other Effects and Factors

Interleukin-1- α as a Modulator of Cytotoxic Drug Activity Against Human Cancer Cells <i>T.C.K. Chan</i>	279
Biological Properties of Human Interleukin-4 <i>J. Blanchereau</i>	287
Interleukin-6 (IL-6)/B Cell Stimulatory Factor 2-Dependent Growth of a Human IGA _{2/K} -Myeloma Cell Line <i>J. Lohmeyer, M. Hadam, N. Kaack, and H. Pralle</i>	293
Purification of a Mast Cell Growth-Enhancing Activity (MEA) Derived from a Murine Interleukin-2-Dependent, M1s ^a -Specific T Cell Line <i>J. Moeller, L. Hültner, E. Schmitt, and P. Dörmer</i>	299
Mast Cell Growth-Enhancing Activity (MEA) is a Potent Inducer of Interleukin-6 Production in a Murine Interleukin-3- Dependent Mast Cell Line <i>L. Hültner, J. Moeller, and P. Dörmer</i>	305
Monocyte-Conditioned Medium Factor as Auto-activation Signal for Monocyte Tumor Cytotoxicity <i>H.H. Spanjer, H.M. Dilling, T.G.J. de Boer, G.B. Humphrey, and W.A. Kamps</i>	311
A Lymphokine Distinct from IL-2 and IL-4 with Proliferative Activity for a CD4 ⁺ T Cell Clone is Preferentially Produced by T _H 2 Cells <i>E. Schmitt, R. van Brandwijk, and E. Rüde</i>	319
Leukoregulin Enhancement of Tumor Inhibitory Drug Uptake <i>C.H. Evans and P.D. Baker</i>	331
Increased Release of Cytokines from Human Peripheral Blood Mononuclear Cells by the β -Galactoside-Specific Lectin from Clinically Applied Mistletoe Extract <i>T. Hajto, K. Hostanska, K. Frei, and H.J. Gabius</i>	337
In Vitro Immunomodulatory Effects of the Thrombocytic Protein C 24 <i>A. Klein-Struckmeier, H. Mohr, and H. Heinze</i>	343
Degree of O- and N-Glycosylation of Lymphokines Released from A 23187-/TPA-Induced Lymphocytes Varies Differently with Culture Time <i>H. Mohr and J. Knüver-Hopf</i>	351
Phorbol Myristate Acetate and Calcium Ionophore A23187 Induce Two Waves of Lymphokine mRNA Transcription in Stimulated Human Peripheral Blood Lymphocytes <i>H. Heinze and H. Mohr</i>	359

Comparison of the Engraftment Promoting Potential of High-Dose Cytostatic Agents in Allogeneic Bone Marrow Transplantation <i>W. Gassmann, L. Uharek, A. Erbersdobler, H.-U. Wottge, H. Loeffler, and W. Mueller-Ruchholtz</i>	365
---	-----

Clinical Data

GM-CSF	375
Hematopoietins as Adjuvant Therapy in Cancer Patients <i>F. Herrmann, W. Oster, A. Lindemann, and R. Mertelsmann</i>	375
Effect of Chemotherapy Followed by GM-CSF for Acute Leukemias at Higher Age or After Relapse <i>T. Büchner, W. Hiddemann, M. Koenigsmann, M. Zühlendorf, B. Wörmann, A. Böckmann, E. Aguion Freire, G. Innig, G. Maschmeyer, W.-D. Ludwig, C.-M. Sauerland, and G. Schulz</i>	387
Growth Response of Acute Myeloid Leukemic Blasts to GM-CSF In Vitro and In Vivo-Observations in One Patient <i>W. Hiddemann, M. Zühlendorf, B. Wörmann, M. Koenigsmann, and T. Büchner</i>	403
Recombinant Human Granulocyte-Macrophage Colony-stimulating Factor After Autologous Bone Marrow Transplantation <i>H. Link, S. Burdach, J. Seidel, H. Diedrich, H. Kirchner, M. Freund, W. Ebell, P. Bucszy, H. Riehm, K. Welte, N. Schmitz, G. Schulz, and H. Poliwoda</i>	411
Recombinant Human GM-CSF for Large-Scale Collection of Circulating Hematopoietic Progenitors in Cancer Patients Treated with High-Dose Cyclophosphamide <i>S. Siena, M. Bregni, F. Ravagnani, B. Brando, G. Bonadonna, and A.M. Gianni</i>	419
Recombinant Human Granulocyte-Macrophage Colony-stimulating Factor for the Mobilization of Hemopoietic Progenitors Prior to Autologous Peripheral Blood Stem Cell Transplantation <i>R. Haas, U. Bredthauer, M. Körbling, and W. Hunstein</i>	427
G-CSF	433
Granulocyte Colony-stimulating Factor: Preclinical and Clinical Effects <i>K. Welte</i>	433

Biology and Clinical Applications of Human Granulocyte Colony-Stimulating Factor	
<i>A.A. Jakubowski and J.L. Gabrilove</i>	449
M-CSF	459
In Vivo Evaluations of Recombinant Human Macrophage Colony-stimulating Factor	
<i>J.B. Stoudemire and M.B. Garnick</i>	459
Interleukin-3	469
The In Vivo Effects of IL-3 and GM-CSF in Primates	
<i>P. Valent, K. Geissler, P. Mayer, B. Volc-Platzer, E. Liehl, and P. Bettelheim</i>	469
Erythropoietin	475
IL-3-Enhanced EPO Effects in Subhuman Primates	
<i>D. Krumwieg, E. Weinmann, B. Siebold, and F.R. Seiler</i>	475
Use of Recombinant Human Erythropoietin after Bone Marrow Transplantation	
<i>H. Link, B. Sens, H. Diedrich, P. Bucsky, W. Ebell, J. Seidel, M. Stoll, M. Freund, J. Tischler, T. Brune, H. Riehm, and H. Poliwoda</i>	483
The Effect of Erythropoietin on Neutrophil Production from Fetal Hematopoietic Progenitors	
<i>R.D. Christensen</i>	489
Response of Premature Anemic Infants to Subcutaneous Recombinant Erythropoietin	
<i>D.S. Halpérin, P. Wacker, G. Lacourt, M. Félix, J.-F. Babel, M. Aapro, and M. Wyss</i>	495
Interferons	505
Interferon-α_{2b} as Therapy for Untreated and Pretreated Patients with Ph¹ Positive Chronic Myelogenous Leukemia	
<i>E. Morra, G. Alimena, M. Lazzarino, A.M. Liberati, E. Montefusco, D. Inverardi, P. Bernasconi, M. Mancini, E. Donti, F. Dianzani, F. Grignani, C. Bernasconi, and F. Mandelli</i>	505

Interferon- α_{2b} in Chronic Myelogenous Leukemia: Experience with Two Treatment Regimen <i>M. Freund, P. von Wussow, F. Hild, F. Buchholz, Th. Buhr, J. Tischler, R. Eisert, O. Koch, S. LeBlanc, B. Blessmann, S. Stiller, H.D. Kleine, G. Exeriede, W. Hiddemann, H. Link, H. Wilke, C. Fonatsch, and H. Poliwoda</i>	515
Heterogeneous Progenitor Sensitivity to Various Cytokines in Patients with Myeloproliferative Disorders; Correlation of In Vitro Interferon- α Sensitivity with the Clinical Responsiveness to Recombinant Interferon- α <i>D. Geissler, G. Gastl, W. Aulitzky, H. Tilg, S. Gaggli, and C. Huber</i>	525
Influence of Busulfan or Interferon- α Treatment on CFU-C from Bone Marrow and Peripheral Blood in Patients with CML in Chronic Phase <i>G. Exeriede, G. Doering, E. Lux, H. Poliwoda, and M. Freund</i>	539
Incomplete Stroma Formation by Bone Marrow from Chronic Myeloid Leukemia Patients Treated with Interferon <i>A. Rice, J. Reiffers, Ph. Bernard, C. Foures, E. Bascans, G. Marit, and A. Broustet</i>	543
Polymerase Chain Reaction for the Detection of Chimeric BCR/ABL mRNA in Patients with Chronic Myelogenous Leukemia (CML)-Detection of Minimal Residual Leukemic Cells After Bone Marrow Transplantation <i>G. Dölken, W. Lange, W. Siegert, R. Herkert, J. Finke, and G.W. Löhr</i>	551
Interferon- α in the Treatment of Chronic Myeloproliferative Disorders with Thrombocytosis <i>H.L. Seewann, C. Schmid, and M. Micksche</i>	561
Recombinant Interferon- α , but not Interferon- γ , is Effective Therapy for Essential Thrombocythemia <i>M.J.B.P. Abegg-Werter, J.M.M. Raemaekers, B.E. de Pauw, and C. Haanen</i>	569
The Role of Interferon- α_2 (IFN- α_2) in the Treatment of Low-Grade Non-Hodgkin's Lymphoma. Preliminary Results of a Randomized Study: IFN- α_2 Plus Chlorambucil Versus Chlorambucil Alone <i>T. Chisesi, L. Rancan, G. Capnist, G. Santini, A. Porcellini, R. Sertoli, A. Contu, V. Rizzoli, P. Coser, and F. Benedetti</i>	575

Evaluation of Myelotoxic Effects in Non-Hodgkin's Lymphomas Treated with Interferon- α and Chlorambucil <i>L. Teofili, G. Leone, B. Rocca, V. De Stefano, M. Messore, G. Nicoletti, and B. Bizzi</i>	583
Response of Early Stage B-CLL to Interferon- α : 2 Years Experience of a Pilot Study <i>R. Schlag, H.W.L. Ziegler-Heitbrock, D. Flieger, and E. Thiel</i>	589
Successful Treatment of Angioimmunoblastic Lymphadenopathy (AIL) and B Cell Prolymphocytic Leukemia (B-PLL) with Interferon- α <i>P. Trinkler, D. Mustroph, H. Hagenah, H. Mönch, and H.W. von Heyden</i>	601
Interferon Treatment of Neuroendocrine Gut and Pancreatic Tumors <i>K. Öberg and B. Eriksson</i>	607
Interferon- α_{2b} in Patients with Endocrine Active Tumors <i>C. Schöber, F. Schuppert, M. Stahl, H. Köhne-Wömpner, H. Wilke, H.-J. Schmoll, and H. Poliwoda</i>	615
Recombinant Interferon- α_{2b} in Patients with Advanced Osteosarcoma after Aggressive Chemotherapy <i>H.-J. Tischler, M. Freund, A. Harstrick, Ch. Schöber, H. Poliwoda, and H.-J. Schmoll</i>	625
HIV-Associated Kaposi's Sarcoma Treated with Recombinant Interferon- α_{2b} : Long-term Results <i>A. Plettenberg, P. Kern, A. Klare, M. Dietrich, and W. Meigel</i>	631
Acute Effects of Recombinant IFN- γ on White Blood Cell Counts and Lymphocyte Subsets in the Peripheral Blood of Cancer Patients <i>W.E. Aulitzky, W. Aulitzky, G. Gastl, B. Lanske, J. Reitter, J. Frick, H. Tilg, M. Berger, M. Herold, and Ch. Huber</i>	639
Tumor Necrosis Factor	645
Phase I Clinical Studies of Tumor Necrosis Factor in Patients with Advanced Cancer <i>A.A. Jakubowski, J.L. Gabrilove, P.B. Chapman, E.S. Casper, H.F. Starnes, and H.F. Oettgen</i>	645
Increase of TNF- α Serum Levels in Major Transplant-Related Complications of Human Bone Marrow Transplantation—Association with Acute Graft-Versus-Host Disease and Activation of Host Macrophages <i>E. Holler, H.J. Kolb, S. Liesenfeld, A. Möller, J. Kempeni, G. Chmel, W. Lehmacher, B. Gleixner, J. Mittermüller, C. Riedner, and W. Wilmanns</i>	653

Interleukin-2	661
IL-2 and Cellular Therapy: Lymphokine-Activated Killer Cells and Tumor-Derived Activated Cells <i>R. Oldham, J. Maleckar, W. West, and J. Yannelli</i>	661
Sequential Bolus Administration of rIL-2 (RU 49637) in Treatment of Advanced Solid Malignancies <i>D. Blaise, A.M. Stoppa, M. Brandelys, M.A. Cappiello, D. Olive, J. Gabert, R. Favre, D. Hans, A.P. Blanc, M. Resbeut, M. Sayag, J.J. Bonnerandi, and D. Maraninchi</i>	673
rIL-2 Immunotherapy for 19 Children with Advanced Metastatic Neuroblastoma <i>M.C. Favrot, J. Michon, E. Bouffet, S. Négrier, P. Cochat, D. Floret, M. Gaspard, C. Coze, G. Andreu, C.R. Franks, I. Philip, and T. Philip</i>	683
Interleukin-2 (IL-2) After Autologous Bone Marrow Transplantation (BMT): A Pilot Study of Late Administration, 2–3 Months Post ABMT <i>D. Maraninchi, D. Blaise, D. Olive, M. Attal, M.H. Gaspard, D. Boule, C. Jasmin, C. Pourreau, P. Palmer, S. Négrier, and I. Philip</i>	691
IL-2 Treatment in a Patient with Stage IV Neuroblastoma After Allogeneic Bone Marrow Transplantation <i>R. Dopfer, R. Handgretinger, T. Klingebiel, P. Reuland, T. Eppinger, H. Scheel-Walter, G. Ehninger, and D. Niethammer</i>	699
Regional Adoptive Immunotherapy for Hepatic Metastasis <i>U. Keilholz, B. Brado, P. Schlag, W. Tilgen, and W. Hunstein</i>	707
Adoptive Immunotherapy with IL-2 in 27 Patients with Metastatic Renal Cell Carcinoma <i>S. Négrier, T. Philip, A. Mercatello, E. Tognet, I. Philip, J.T. Bijman, J.F. Moskovtchenko, and M. Favrot</i>	713
Adoptive Immunotherapy of Advanced Cancer with LAK Cells and Different Dosages of Interleukin-2: Analysis of Lymphocyte Subpopulations <i>P. Samoggia, E.M. Ruggeri, G. Mariani, P. Carlini, G. Salvo, G. Giannella, D. Habetswallner, E. Montesoro, M.G. Arena, R. Masciulli, D. Bulgarini, G. Petrillo, C.F. Pollera, P. Marolla, S. Natali, G. Boccoli, G. Mastroberardino, G. Isacchi, U. Testa, F. Calabresi and C. Peschle</i>	721

Natural Interleukin-2 plus Lymphokine-Activated Killer Cells in Patients with Advanced Malignancy

*H. Link, M. Freund, B. Sens, A. Hoffmann, J. Atzpodien,
H. Kirchner, M. Stahl, C. Schöber, H.J. Schmoll, J. Andres,
Th. Volgmann, H. Mohr, U. Pohl, and H. Poliwoda* 729

Evaluation of In Vivo Natural Killer and Lymphokine-Activated Killer Cell Activity in Patients Treated with High-Dose Interleukin-2 and Adoptive Transfer of Autologous LAK Cells

J. Walewski, E. Paietta, J. Dutcher, and P.H. Wiernik 735

Immunological Monitoring of Cancer Patients During a Phase I/II Clinical Trial of Natural Interleukin-2

*G. Pawelec, H. Schlag, U. Schwuléra, H. Lenz, E. Schneider,
K. Schaudt, H.J. Bühring, and G. Ehninger*..... 743

Antibodies to Interleukin-2 (IL-2) in Patients: Cross Reactivity with Different IL-2 Species

H. Mohr, J. Knüver-Hopf, J. Atzpodien, H. Kirchner, and U. Pohl 751

Subject Index 757